Background Acute myeloid leukaemia (AML) is an aggressive blood cancer. In
approximately 30% of the cases, driver mutations in the FLT3 gene are identified. FLT3 …

Background Acute myeloid leukaemia (AML) remains difficult to treat despite the
development of novel formulations and targeted therapies. Activating mutations in the FLT3 …

Acute myeloid leukemia (AML) is a heterogeneous disease and remains a therapeutic
challenge. Cytogenetics is a well-established prognostic factor. Recent discovery of …

The advent of small molecule-based targeted therapy has improved the treatment of both
acute and chronic leukemias. Resistance to small molecule inhibitors has emerged as a …

Purpose: Biomarkers of response and resistance to FLT3 tyrosine kinase inhibitors (TKI) are
still emerging, and optimal clinical combinations remain unclear. The purpose of this study is …

Genomic studies have revealed significant branching heterogeneity in cancer. Studies of
resistance to tyrosine kinase inhibitor therapy have not fully reflected this heterogeneity …

Acute myeloid leukemia remains associated with poor outcomes despite advances in our
understanding of the complicated molecular events driving leukemogenesis and malignant …

FLT3 mutations are prevalent in AML patients and confer poor prognosis. Crenolanib, a
potent type I pan-FLT3 inhibitor, is effective against both internal tandem duplications and …

FMS‐like tyrosine kinase 3 (FLT3) has been found to be mutated in~ 30% of acute myeloid
leukaemia patients. Small‐molecule inhibitors targeting FLT3 that are currently approved or …

FLT3-ITD and FLT3-TKD mutations were observed in approximately 20 and 10% of acute
myeloid leukemia (AML) cases, respectively. FLT3 inhibitors such as midostaurin, gilteritinib …